Asthma remission.
作者信息
O'Byrne Paul M
机构信息
Firestone Institute for Respiratory Health and the Department of Medicine, McMaster University, Hamilton, Ontario, Canada.
出版信息
J Bras Pneumol. 2024 Mar 22;50(1):e20240004. doi: 10.36416/1806-3756/e20240004.
Abstract
摘要
相似文献
1
Asthma remission.哮喘缓解
J Bras Pneumol. 2024 Mar 22;50(1):e20240004. doi: 10.36416/1806-3756/e20240004.
2
Biologics in Asthma: Potential to Achieve Clinical Remission.哮喘中的生物制剂：实现临床缓解的潜力。
Immunol Allergy Clin North Am. 2024 Nov;44(4):725-736. doi: 10.1016/j.iac.2024.08.004. Epub 2024 Sep 6.
3
Spanish Consensus on Remission in Asthma (REMAS).西班牙哮喘缓解共识（REMAS）。
Arch Bronconeumol. 2024 Aug;60(8):503-509. doi: 10.1016/j.arbres.2024.04.002. Epub 2024 Apr 23.
4
Remission in asthma.哮喘缓解。
Curr Opin Pulm Med. 2024 May 1;30(3):325-329. doi: 10.1097/MCP.0000000000001068. Epub 2024 Mar 5.
5
Remission of asthma in the middle aged and elderly: report from the Obstructive Lung Disease in Northern Sweden study.中老年哮喘的缓解：来自瑞典北部阻塞性肺病研究的报告。
Thorax. 1999 Jul;54(7):611-3. doi: 10.1136/thx.54.7.611.
6
The Relationship of Asthma Biologics to Remission for Asthma.哮喘生物制剂与哮喘缓解的关系。
J Allergy Clin Immunol Pract. 2021 Mar;9(3):1090-1098. doi: 10.1016/j.jaip.2020.10.035. Epub 2020 Oct 28.
7
[The development of remission in patients with bronchial asthma].[支气管哮喘患者缓解期的发展]
Vutr Boles. 1990;29(2):35-40.
8
An expert consensus framework for asthma remission as a treatment goal.哮喘缓解作为治疗目标的专家共识框架。
J Allergy Clin Immunol. 2020 Mar;145(3):757-765. doi: 10.1016/j.jaci.2019.12.006. Epub 2019 Dec 19.
9
Asthma remission: what is it and how can it be achieved?哮喘缓解：它是什么，以及如何实现？
Eur Respir J. 2022 Nov 3;60(5). doi: 10.1183/13993003.02583-2021. Print 2022 Nov.
10
Clinical remission in severe asthma: lights and shadows on an ambitious goal.严重哮喘的临床缓解：一个雄心勃勃目标的光明与阴影。
Curr Opin Allergy Clin Immunol. 2024 Aug 1;24(4):230-236. doi: 10.1097/ACI.0000000000000991. Epub 2024 Apr 30.
本文引用的文献
1
Pioneering a paradigm shift in asthma management: remission as a treatment goal.开创哮喘管理的范式转变：将缓解作为治疗目标。
Lancet Respir Med. 2024 Feb;12(2):96-99. doi: 10.1016/S2213-2600(23)00415-0. Epub 2023 Dec 7.
2
Clinical remission in severe asthma with biologic therapy: an analysis from the UK Severe Asthma Registry.生物疗法治疗重症哮喘的临床缓解：来自英国重症哮喘注册研究的分析。
Eur Respir J. 2023 Dec 14;62(6). doi: 10.1183/13993003.00819-2023. Print 2023 Dec.
3
Remission outcomes in severe eosinophilic asthma with mepolizumab therapy: Analysis of the REDES study.美泊利珠单抗治疗重症嗜酸性粒细胞性哮喘的缓解结局：REDES 研究分析。
Front Immunol. 2023 Apr 12;14:1150162. doi: 10.3389/fimmu.2023.1150162. eCollection 2023.
4
A Real-World Study of Achievement Rate and Predictive Factors of Clinical and Deep Remission to Biologics in Patients with Severe Asthma.重度哮喘患者使用生物制剂实现临床和深度缓解的成功率及预测因素的真实世界研究
J Clin Med. 2023 Apr 16;12(8):2900. doi: 10.3390/jcm12082900.
5
Asthma remission: what is it and how can it be achieved?哮喘缓解：它是什么，以及如何实现？
Eur Respir J. 2022 Nov 3;60(5). doi: 10.1183/13993003.02583-2021. Print 2022 Nov.
6
Clinical Remission in Severe Asthma: A Pooled Post Hoc Analysis of the Patient Journey with Benralizumab.严重哮喘的临床缓解：贝那鲁肽治疗患者的路径的汇总事后分析。
Adv Ther. 2022 May;39(5):2065-2084. doi: 10.1007/s12325-022-02098-1. Epub 2022 Mar 14.
7
Defining a Severe Asthma Super-Responder: Findings from a Delphi Process.定义重度哮喘超高反应者：德尔菲法研究结果。
J Allergy Clin Immunol Pract. 2021 Nov;9(11):3997-4004. doi: 10.1016/j.jaip.2021.06.041. Epub 2021 Jul 13.
8
Trends in worldwide asthma prevalence.全球哮喘患病率的趋势。
Eur Respir J. 2020 Dec 24;56(6). doi: 10.1183/13993003.02094-2020. Print 2020 Dec.
9
An expert consensus framework for asthma remission as a treatment goal.哮喘缓解作为治疗目标的专家共识框架。
J Allergy Clin Immunol. 2020 Mar;145(3):757-765. doi: 10.1016/j.jaci.2019.12.006. Epub 2019 Dec 19.
10
Efficacy and Safety of Dupilumab in Glucocorticoid-Dependent Severe Asthma.度普利尤单抗治疗糖皮质激素依赖型重症哮喘的疗效和安全性。
N Engl J Med. 2018 Jun 28;378(26):2475-2485. doi: 10.1056/NEJMoa1804093. Epub 2018 May 21.
Zotero 插件